In HNSCC, immune checkpoint inhibitors (ICIs) that target PD-1, pembrolizumab and nivolumab are currently used in metastatic or recurrent (R/M) HNSCC based on survival benefits [7]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.